Parkinson ' s disease (PD) is defi ned by the degeneration of nigral dopaminergic (DA) neurons and can be caused by monogenic mutations of genes such as parkin. The lack of phenotype in parkin knockout mice suggests that human nigral DA neurons have unique vulnerabilities. Here we generate induced pluripotent stem cells from normal subjects and PD patients with parkin mutations. We demonstrate that loss of parkin in human midbrain DA neurons greatly increases the transcription of monoamine oxidases and oxidative stress, signifi cantly reduces DA uptake and increases spontaneous DA release. Lentiviral expression of parkin, but not its PD-linked mutant, rescues these phenotypes. The results suggest that parkin controls dopamine utilization in human midbrain DA neurons by enhancing the precision of DA neurotransmission and suppressing dopamine oxidation. Thus, the study provides novel targets and a physiologically relevant screening platform for disease-modifying therapies of PD. arkinson ' s disease (PD) is clinically defi ned by a core set of motor symptoms that are believed to be caused by the degeneration of dopaminergic (DA) neurons in substantia nigra 1 . A variety of environmental and genetic factors underlie the accelerated degeneration of nigral DA neurons in PD 2 . Although monogenic forms of PD account for a small percentage of cases 2 , understanding how mutations of these genes lead to the selective degeneration of nigral DA neurons holds great promise to the discovery of disease-modifying therapies for PD. Among the genes that have been causatively linked to PD, parkin is unique in that its mutations are most frequently found in recessively inherited PD cases; they are completely penetrant and do not have a founder eff ect 3 . Parkin is an ubiquitin-protein ligase 4 for a variety of substrates 5 . In sharp contrast to the situation seen in PD patients with parkin mutations 6 , parkin knockout mice do not exhibit any robust phenotype 7 , suggesting that parkin mutations selectively impact on human nigral DA neurons.
P
arkinson ' s disease (PD) is clinically defi ned by a core set of motor symptoms that are believed to be caused by the degeneration of dopaminergic (DA) neurons in substantia nigra 1 . A variety of environmental and genetic factors underlie the accelerated degeneration of nigral DA neurons in PD 2 . Although monogenic forms of PD account for a small percentage of cases 2 , understanding how mutations of these genes lead to the selective degeneration of nigral DA neurons holds great promise to the discovery of disease-modifying therapies for PD. Among the genes that have been causatively linked to PD, parkin is unique in that its mutations are most frequently found in recessively inherited PD cases; they are completely penetrant and do not have a founder eff ect 3 . Parkin is an ubiquitin-protein ligase 4 for a variety of substrates 5 . In sharp contrast to the situation seen in PD patients with parkin mutations 6 , parkin knockout mice do not exhibit any robust phenotype 7 , suggesting that parkin mutations selectively impact on human nigral DA neurons.
One of the major roadblocks in PD research is the lack of live human midbrain DA neurons. Th e discovery of human induced pluripotent stem cells (iPSCs) 8, 9 has allowed us in this study to generate patient-specifi c iPSCs, which were diff erentiated in vitro to midbrain DA neurons for mechanistic studies of parkin. We fi nd that parkin mutations in iPSC-derived human midbrain DA neurons signifi cantly elevates oxidative stress induced by dopamine oxidation because the transcription of monoamine oxidases A and B greatly increases. Specifi c dopamine uptake through dopamine transporter (DAT) signifi cantly decreases, as the amounts of DATbinding sites signifi cantly reduce. In addition, spontaneous Ca 2 + -independent release of dopamine signifi cantly increases while activity-and Ca 2 + -dependent DA release remains the same. Th ese dopamine-specifi c phenotypes can be signifi cantly reversed by lentiviral expression of wild-type parkin, but not its PD-linked T240R mutant or green fl uorescent protein (GFP). Th e results not only reveal mechanistic insights into the cellular functions of parkin in human midbrain DA neurons -the cell type selectively impacted by its mutations, they also provide novel targets and a screening platform for the discovery of disease-modifying agents that can mimic the protective functions of parkin.
Results

Generation of iPSCs from PD patients with parkin mutations .
To understand why mutations of parkin cause the selective degeneration of human nigral DA neurons and ensuing PD 6 , we generated iPSCs using dermal fi broblasts from two PD patients with parkin mutations (one with compound heterozygous deletions of exon 3 and exon 5, designated as P001; the other with homozygous deletion of exon 3, designated as P002) and two control subjects (designated as C001 and C002) who are unrelated, unaff ected spouses of idiopathic PD patients. Dermal fi broblasts cultured from skin punch biopsy were reprogrammed to iPSCs using lentiviruses expressing human Oct4, Sox2, Klf4, c-Myc and Nanog 10 . Multiple clones with human embryonic stem cell (hESC) morphology were picked for each of the four subjects. Aft er expansion and initial characterization, one representative clone for each subject (C001 # 2, C002 # 1, P001 # 3, P002 # 4.5) was used for detailed studies. As shown in Figure 1 for P002 iPSC and Supplementary Figure S1 for the other three lines, all four lines of iPSCs exhibited morphology indistinguishable from hESCs such as H9 and can be maintained indefi nitely on mouse embryonic fi broblast feeders or matrigel. Pluripotency markers such as alkaline phosphatase, Oct4, Nanog, SSEA3, SSEA4, Tra-1-60 and Tra-1-81 were strongly expressed in all four lines. Real-time quantitative reverse transcriptase PCR (qRT -PCR) showed that a panel of endogenous pluripotency genes (except NODAL ) were expressed at levels comparable to those in H9 hESC ( Fig. 1i and Supplementary Fig. S1y ). Sequences of PCR primers are listed in Supplementary Table S1 . Th e reason for the low level of NODAL is unclear and might be related to our iPSC-derivation method and condition (for example, we used 5 % O 2 in iPSC derivation and culture). DNA methylation in the promoter regions of Oct4, Nanog and Sox2 was greatly reduced in the four lines of iPSCs, in comparison to that in the original fi broblast lines ( Supplementary  Fig. S2 ). Th e promoter sequences are listed in Supplementary Table  S2 . Th e fi ve viral transgenes were strongly silenced in these iPSCs ( Fig. 1j ; Supplementary Fig. S1y ). RT -PCR was performed on total RNA from the four lines of iPSCs grown on matrigel to confi rm parkin mutations in the two PD patients ( Fig. 1k ) . Th e RT -PCR products were sequenced to verify that P001 iPSC indeed had compound heterozygous deletions of exon 3 and exon 5 while P002 iPSC had homozygous deletion of exon 3 ( Fig. 1l,m ) . Western blotting of total cell lysates from the four lines of iPSCs confi rmed that parkin was not expressed in P001 and P002 cells ( Fig. 1n ) . In embryoid body-mediated spontaneous diff erentiation assays, all four lines of iPSCs could be diff erentiated to cells of the three germ layers ( Fig. 1o -q for P002 and Supplementary Fig. S3 for the other three lines). Th ey also formed teratomas under kidney capsules in SCID mice ( Fig. 1r -t for P002 and Supplementary Fig. S3 for the other three lines). All four lines of iPSCs showed normal karyotypes ( Supplementary Fig. S4 ). Th is was confi rmed by array comparative genomic hybridization, which showed no signifi cant chromosomal change in the iPSCs when compared with pooled normal human genomic DNA ( Supplementary Fig. S5 ).
Diff erentiation of iPSCs to midbrain DA neurons . We used a feeder-free, chemically defi ned, directed diff erentiation protocol 11 to diff erentiate the four lines of iPSCs to midbrain DA neurons in vitro ( Fig. 2 ) . Th e iPSC colonies dissociated from mouse embryonic fi broblast cells were fi rst cultured as fl oating cell aggregates (EB) for 4 days in hESC medium with 10 μ M SB431542 to enhance neural diff erentiation 12 . Aft er the cell aggregates were cultured in suspension in the presence of 20 ng ml − 1 bFGF for two more days, they were plated on laminin-coated surface. Many colonies had an elongated columnar morphology. Th ese primitive neuroepithelial cells were diff erentiated to defi nitive neuroepithelia in the presence of FGF8a (20 ng ml − 1 ) and SHH (100 ng ml − 1 ). Multiple neural tube-like rosettes were seen in the centre of the colony ( Fig. 2b ) . Th e rosettes were peeled off from the fl at peripheral cells and cultured in suspension in the presence of FGF8a (50 ng ml − 1 ) and SHH (100 ng ml − 1 ), B27 supplements (1 × ) and ascorbic acid (200 μ M) to form neurospheres that were patterned to a mid / hind brain destiny ( Fig. 2c ) . Around day 24, the neurospheres were dissociated and plated on 6-well plates or cover slips precoated with polyornithine, laminin and matrigel. We found that the addition of matrigel coating signifi cantly inhibited the formation of cell aggregates during the last step of diff erentiation and might have contributed to the improved DA characteristics, such as specifi c dopamine uptake. Trophic factors such as BDNF (20 ng ml − 1 ) and GDNF (20 ng ml − 1 ) were used to generate mature DA neurons, which were seen around 70 days from the start of diff erentiation ( Fig. 2d ) .
P002 iPSC-derived neuronal cultures contained TH + neurons with complex morphology and in clusters (for example, Fig. 3a,b ) . Th ese TH + neurons expressed the midbrain markers engrailed-1 (En-1) 13 ( Fig. 3a ) and FoxA2 ( Fig. 3b ) , as well as other DA markers such as AADC ( Fig. 3c ) , DAT ( Fig. 3d ) and VMAT2 ( Fig. 3e ) , suggesting that they are midbrain DA neurons. Th ey expressed synaptic markers such as synaptophysin ( Fig. 3f ) and NR1 ( Fig. 3g ) , and markers for mature neurons such as MAP2 ( Fig. 3h ) . Similar expression of these markers was seen in neuronal cultures derived from C001, C002 and P001 iPSC lines ( Supplementary Fig. S6 ). Consistent with this, RT -PCR experiments showed that TH, En-1, AADC, DAT, VMAT2, Nurr1, Ptx3, FoxA2 and Lmx1b were strongly expressed in iPSC-derived neurons, but not in the iPSCs ( Supplementary Fig. S7 ) . Th e weak expression of FoxA2 and Lmx1b in our iPSCs was similar to what has been reported before 14, 15 . qRT -PCR experiments showed that there were very low levels of viral transgene expression in the four lines of iPSC-derived neurons ( Supplementary Fig. S8 ). Similar to what has been reported recently for the diff erentiation of iPSCs to motor neurons 16 , the low level of transgene expression in our iPSC-derived neurons did not appear to aff ect the diff erentiation or function of these neurons, as electrophysiological studies showed that P002 neurons fi red spontaneous action potentials (APs; Fig. 3i ) and evoked APs ( Fig. 3j ) . Th ey have voltage-gated K + currents and voltage-gated Na + currents ( Fig. 3k ) , N -methyl-d -aspartic acid (NMDA)-gated currents ( Fig. 3l ) , γ -aminobutyric acid (GABA)-gated currents ( Fig. 3m ) and spontaneous excitatory postsynaptic currents ( Fig. 3n ) . Similar electrophysiological profi les were observed in neurons derived from C001, C002 and P001 iPSCs ( Supplementary Fig. S9 ). Th ese results showed that all four lines of iPSC-derived neuronal cultures had synaptic transmission and contained midbrain DA neurons.
Parkin mutations increased spontaneous DA release . To demonstrate that these midbrain DA neurons are functional, we measured spontaneous and activity-dependent dopamine release by reverse phase high pressure liquid chromatography (HPLC) coupled with electrochemical detection of dopamine 17 . Th e iPSC-derived neuronal cultures were incubated at 37 ° C in Hank ' s Balanced Salt Solution (HBSS), HBSS with 56 mM KCl or Ca 2 + -free HBSS with 56 mM KCl. Spontaneous DA release in HBSS (30 min) was robustly observed in all four lines of iPSC-derived DA neurons and was signifi cantly increased in P001 and P002, compared with C001 or C002 ( P < 0.05, n = 3 -8, Student ' s t -test, unpaired, two-tailed) ( Fig. 4a ) . DA release was markedly increased by KCl-induced membrane depolarization in the four lines of DA neurons, and the increases were abolished when Ca 2 + -free HBSS was used with KCl ( Fig. 4a ) . Ca 2 + -and activity-dependent release was calculated by the diff erence between KCl-induced DA release in the presence and absence of Ca 2 + ; it was not signifi cantly diff erent among the four lines of DA neurons ( Fig. 4b ) . To ascertain that increased spontaneous DA release was indeed caused by the loss of parkin, we infected P001 or P002 neurons with lentivirus expressing GFP or FLAG-tagged parkin or its PD-linked T240R mutant. Overexpression of wild-type parkin, but not its T240R mutant or GFP, signifi cantly reduced spontaneous DA release in HBSS from P001 or P002 neurons ( P < 0.05 versus P001 or P002 expressing GFP, respectively, n = 4, Student ' s t -test, unpaired, two-tailed) ( Fig. 4c ) . Th e spontaneous dopamine release was not signifi cantly aff ected by selective inhibitors of DAT such as GBR12909 (10 μ M) or nomifensine (10 μ M) ( Supplementary Fig. S10a ), suggesting that it is not caused by dopamine effl ux through DAT. Total dopamine content in these neuronal cultures as measured by HPLC was not signifi cantly diff erent ( Fig. 4d ) . We counted more than 1000 NeuN + neurons for each line. Th e percentage of TH + neurons in NeuN + neurons was not signifi cantly diff erent ( Fig. 4e ) . We plated the same number of neuroepithelial cells at the last step of diff erentiation. Th e total number of neurons were too numerous to count. Th us, the similar percentages of TH + neurons suggest that the numbers of DA neurons are similar across the four lines.
Parkin mutations decreased DA uptake and DAT-binding sites . We measured specifi c DA uptake by incubating the neuronal cultures for 10 min at 37 ° C with 5 μ M dopamine in the absence or presence of 10 μ M nomifensine, a selective inhibitor of DAT. Th e condition was based on the dose response and time course of dopamine uptake in C001 neurons ( Supplementary Fig. S10b,c ) . Th e ligand concentration (5 μ M) was very close to V max condition and the duration (10 min) was in the linear phase of uptake. It was used before in our previous study 18 and was consistent with other studies using cloned human DAT in exogenous expression systems 19, 20 . Th e amount of dopamine in the cells as measured by HPLC was used to calculate specifi c DA uptake, which is the diff erence of DA uptake in the absence and presence of nomifensine. Non-specifi c DA uptake in the presence of nomifensine was not signifi cantly diff erent between the four lines of iPSC-derived neurons (data not shown). Furthermore, dopamine uptake was not signifi cantly aff ected by nisoxetine (0.1 μ M), a selective inhibitor of norepinephrine transporter ( Supplementary Fig. S10d ). As shown in Figure 4f , specifi c DA uptake was signifi cantly diminished in P001 and P002 DA neurons, compared with C001 or C002 DA neurons ( P < 0.05, n = 5 -9, Student ' s t -test, unpaired, two-tailed). ( a -h ) P002 iPSC-derived neuronal cultures were co-stained for TH and the midbrain markers engrailed-1 (En-1) ( a ) and FoxA2 ( b ), the DA markers AADC ( c ), dopamine transporter (DAT) ( d ) and VMAT2 ( e ), the synaptic markers synaptophysin ( f ) and NR1 ( g ), and the marker for mature neurons MAP2 ( h ). Bars, 10 μ m. ( i -n ) These neurons fi red spontaneous APs ( i ) and evoked APs ( j ), had voltage-gated K + and Na + currents ( k ), N -methyl-D -aspartic acid (NMDA)-gated currents ( l ), γ -aminobutyric acid (GABA)-gated currents ( m ) and spontaneous EPSC ( n ). Dates (for example, 70 days) indicated were from the start of differentiation. AP, action potential; sEPSC, spontaneous excitatory postsynaptic currents.
versus P001 or P002 expressing GFP, respectively, n = 4, Student ' s t -test, unpaired, two-tailed) ( Fig. 4g ) , suggesting that the eff ect is indeed caused by loss-of-function mutations of parkin in P001 and P002 neurons. Our previous study has shown that parkin enhances the cell surface expression of DAT by ubiquitinating and degrading misfolded DAT to facilitate the oligomerization of native DAT conformers in the endoplasmic reticulum 18 , a prerequisite for the plasma membrane delivery of this misfolding-prone protein 21 . To test whether reduced dopamine uptake in P001 and P002 neurons is caused by a decreased amount of correctly folded DAT that are competent for selective dopamine uptake, we measured the amounts of DAT-binding sites using 18 , a potent cocaine analogue that specifi cally binds to DAT. Th e iPSC-derived neuronal cultures were incubated for 2 h at 4 ° C in binding buff er with 4 nM [ 3 H]CFT in the absence or presence of the selective DAT inhibitor GBR12909 (10 μ M). Total cell lysates, in which [ 3 H]CFT was bound to correctly folded DAT molecules, were measured in a scintillation counter to calculate specifi c [ 3 H]CFT binding on DAT (the diff erence in binding with or without GBR12909). As shown in Figure 4h , specifi c [ 3 H]CFT binding was greatly reduced in P001 and P002 DA neurons, compared with C001 or C002 DA neurons ( P < 0.05, n = 6, Student ' s t -test, unpaired, two-tailed), while the levels of total DAT in whole-cell lysates were very similar. To confi rm that reduced DATbinding sites were indeed caused by parkin mutations in P001 and P002 neurons, we infected these neurons with lentivirus expressing GFP, parkin or its PD-linked T240R mutant. As shown in Figure 4i , overexpression of parkin, but not T240R or GFP, signifi cantly increased the specifi c binding of [ 3 H]CFT in P001 or P002 neurons ( P < 0.05 versus P001 or P002 expressing GFP, respectively, n = 5, Student ' s t -test, unpaired, two-tailed).
Parkin mutations elevated ROS by increasing MAO transcripts .
To test the impact of parkin mutations on dopamine-induced oxidative stress, which has a key role in the selective degeneration of nigral DA neurons in PD 22 , we treated the four lines of iPSCderived neuronal cultures without or with 75 μ M dopamine for 4 h, and examined the level of oxidative stress by measuring the amounts of protein carbonyls in the total cell lysates. Without dopamine treatment, very few protein carbonyls were seen in all four lines of human neurons. Aft er DA treatment, the amounts of protein carbonyls were greatly increased in P001 and P002 neurons, compared with those in C001 or C002 neurons ( P < 0.01, n = 8, Student ' s t -test, unpaired, two-tailed), which only had very modest increases over their basal levels ( Fig. 5a,b ) . Th e results suggest that dopamine-induced oxidative stress is markedly elevated when parkin is mutated. Our previous study has shown that parkin suppresses the transcription of monoamine oxidases (MAO) A and B 17 , which are mitochondrial enzymes responsible for the oxidative deamination of dopamine, a reaction that produces large quantities of reactive oxygen species 23 . When we measured the messenger RNA levels of MAO-A and MAO-B by qRT -PCR, we found that the amounts of MAO-A and MAO-B transcripts were signifi cantly increased in P001 and P002 neurons, compared with those in C001 or C002 neurons ( P < 0.01, n = 9, Student ' s t -test, unpaired, two-tailed) ( Fig. 5c ). To substantiate these fi ndings, we measured the activities of MAO-A or MAO-B in total cell lysates from these neurons using [ 14 C]tyramine as a substrate, and pargyline or clorgyline to inhibit MAO-B or MAO-A, respectively 17 . As shown in Figure 5d , the amounts of MAO-A or MAO-B enzymatic activities were signifi cantly increased in P001 and P002 neurons, compared with those in C001 or C002 neurons ( P < 0.01, n = 6 -11, Student ' s t -test, unpaired, two-tailed).
To ascertain that these phenotypes were indeed caused by parkin mutations, we infected P001 or P002 neurons with lenti virus expressing GFP, FLAG-tagged parkin or T240R mutant parkin. Overexpression of parkin, but not its PD-linked T240R mutant or GFP, signifi cantly lowered the messenger RNA levels of MAO-A and MAO-B in P001 and P002 neurons ( P < 0.05, n = 4, Student ' s t -test, unpaired, two-tailed) ( Fig. 5e,f ) , as well as the activities of MAO-A and MAO-B in total cell lysates from these neurons ( P < 0.05, n = 4, Student ' s t -test, unpaired, two-tailed) ( Fig. 5g,h ). Consistent with these fi ndings, the amounts of protein carbonyls in P001 and P002 neurons were signifi cantly decreased by overexpression of parkin, but not its T240R mutant or GFP ( P < 0.05, n = 3, Student ' s t -test, unpaired, two-tailed) ( Fig. 5i,k ) . Th e expression levels of GFP, FLAG-tagged parkin or its T240R mutant, and p150 glued (as loading control) were shown in Figure 5j .
Parkin mutations did not signifi cantly aff ect mitochondria . We examined whether the loss of parkin signifi cantly aff ect mitochondria by treating the four lines of iPSC-derived neurons without or with CCCP (10 μ M for 16 h) to induce mitophagy 24 . Th ere was no signifi cant change in the amount of mitochondria as refl ected in the quantitative PCR measurement of mitochondrial DNA against the nuclear gene actin ( Fig. 6a -c ) . Th e protein expression levels of PINK1 and DJ-1 in the presence or absence of CCCP (10 μ M for 24 h) were not signifi cantly changed ( Fig. 6d ) . Th e expression levels of α -synuclein were also very similar among the four lines of iPSC-derived neurons ( Fig. 6e ) .
Discussion
One of the critical challenges for PD research is the lack of live human nigral DA neurons for mechanistic studies and drug discovery, as animal models of PD generally do not recapitulate the human condition very well 25 . Th e discovery of human iPSCs 8, 9 makes it possible to generate patient-specifi c midbrain DA neurons to study their unique vulnerabilities in PD, particularly in monogenic forms of PD, in which the mechanistic link between genotype and phenotype is being vigorously pursued. Th e present study showed that parkin mutations directly impinge on dopamine utilization in human midbrain DA neurons.
MAO-A MAO-B MAO-A MAO-B MAO-A MAO-B MAO-A MAO-B MAO-A MAO-B MAO-A MAO-B
Activity
Th e loss of parkin signifi cantly increased the spontaneous DA release that was independent of extracellular [Ca 2 + ] ( Fig. 4a ) , but did not signifi cantly aff ect Ca 2 + -dependent DA release triggered by membrane depolarization ( Fig. 4b ) . It suggests that parkin limits somatodendritic DA release, which can be independent of extracellular [Ca 2 + ] 26, 27 . As parkin is involved in vesicle traffi cking through monoubiquitination of proteins such as Eps15 28 , it seems plausible that parkin may aff ect the recycling of dopamine-containing vesicles that are involved in somatodendritic release. Th ere is a strong feedback mechanism on the activity of TH, the rate-limiting enzyme in the synthesis of dopamine. It serves to maintain the homoeostasis of dopamine between cytosolic and vesicular pool so that increased release may be compensated by increased synthesis. In addition, VMAT2, DAT, MAO and COMT also impact on the homoeostasis of dopamine 29 . Th us, the total amount of endogenous dopamine was not signifi cantly aff ected by parkin mutations ( Fig. 4d ) .
On the other hand, loss of parkin signifi cantly decreased dopamine uptake ( Fig. 4f ) by reducing the total amount of correctly folded DAT ( Fig. 4h ) . Th is is consistent with our previous fi nding that parkin increases the cell surface expression of DAT by ubiquitinating and degrading misfolded DAT conformers to enhance oligomerization of native DAT conformers in the endoplasmic reticulum and their subsequent delivery to the plasma membrane 18 . Recent positron emission tomography studies have shown that 18 F-DOPA uptake is signifi cantly reduced in PD patients with parkin mutations, compared with controls 30, 31 . Th us, mutations of parkin signifi cantly disrupt the spatial and temporal precision of DA neurotransmission by increasing spontaneous DA release and decreasing DA uptake. Th e net outcome is increased extracellular DA level, which was mimicked by the dopamine treatment experiment in Figure 5a . In this paradigm, parkin mutations greatly increased dopamine-induced oxidative stress ( Fig. 5a,b ) because mutant parkin lost the ability to suppress MAO transcription ( Fig. 5c ) . Th is result is consistent with our previous fi nding that parkin suppresses the transcription of monoamine oxidase A and B 17 . It appears that P002 had a particularly high level of MAO-B transcript ( Fig. 5c ) and activity ( Fig. 5d ) , even when compared with P001. Th is might be related to diff erent genetic background of the two patients and / or diff erent parkin mutations that they carry (P002 has homozygous exon 3 deletion, while P001 has compound heterozygous deletion of exon 3 and exon 5). Overexpression of parkin, but not its PD-linked T240R mutant or GFP, rescued all the phenotypes -increased spontaneous DA release, decreased DA uptake and DAT-binding sites, increased MAO transcription and DA-induced oxidative stress ( Figs 4 and 5 ). Th us, these dopamine-specifi c phenotypes are indeed caused by loss-of-function mutations of parkin.
Our fi ndings on dopamine-specifi c functions of parkin also shed light on novel therapeutic targets of PD. Recent studies have shown that MAO-B inhibitors have a signifi cant, albeit modest, eff ort in slowing down the progression of PD 32 . As parkin suppresses MAO transcription by ubiquitinating and degrading estrogen-related receptors 33 , it may be more advantageous to mimic the protective function of parkin by suppressing MAO transcription using inhibitors of estrogen-related receptors (for example, XCT-790) 34 , rather than inactivating MAO activity indiscriminately with suicide substrates such as those used in the current therapy. Alternatively, the ability of parkin to repress p53 35 could also be exploited to achieve similar eff ects. On the other hand, agents that could enhance the folding of native DAT conformers or the elimination of misfolded DAT conformers may be good candidates to substitute parkin in restoring dopamine uptake. Agents that directly enhance DA uptake or increase the cell surface expression of DAT may also be suitable drug candidates.
In conclusion, the study has discovered how mutations of parkin disrupt an essential function of human midbrain DA neuronsthe coordinated utilization of dopamine as a neurotransmitter and the control of dopamine toxicity. Mechanistic insights gained from the study would be very useful for the development of disease-modifying therapies of PD on a platform that closely resembles human nigral DA neurons in vivo . Further studies are needed to address why nigral DA neurons, in comparison with other types of DA neurons, are particularly vulnerable in PD and how parkin protects against these vulnerabilities.
Methods
Derivation of iPSCs from skin fi broblasts . With approvals from the Health Sciences Institutional Review Board of the State University of New York at Buff alo and the Ethics Committee of Tottori University Faculty of Medicine, we obtained informed consents from research subjects participating in this study. Skin punch biopsies (5 mm in diameter or less) were obtained from two PD patients with parkin mutations and two control subjects. Skin fi broblasts (1 × 10 5 ) at passage 2 or 3 were infected for 16 h with the following FUW-tetOLoxP lentiviruses: hOct4, hSox4, hKlf4 and hNanog each at MOI 15, c-Myc at MOI 6 and M2rtTA at MOI 30 in the presence of 4 μ g ml − 1 polybrene 10 . Doxycycline (1 μ g ml − 1 ) was added for at least 10 days and later at 0.5 μ g ml − 1 until hESC-like clones appeared. VPA (0.5 or 1 mM) was added for 7 days with DOX in the beginning. Clones with hESC morphology appeared between day 24 and 40. Th ey were picked and expanded under hESC culture condition. Th e proviruses integrated in the genomes of the four iPSC lines were not removed because a recent study has demonstrated that neural diff erentiation of various iPSCs is not aff ected by the absence or presence of proviruses introduced during reprogramming 36 . Dopamine release . Th e iPSC-derived neuronal cultures diff erentiated at the same conditions in 6-well plates were treated at 37 ° C in the following way for each set of three wells (a, b and c). Well (a) was incubated in 1 ml HBSS for 30 min. Well (b) was incubated in 1 ml HBSS for 15 min and then 56 mM KCl was added for another 15 min. Well (c) was incubated in 1 ml HBSS without Ca 2 + and without Mg 2 + , but with 2 mM EDTA for 15 min and then 56 mM KCl was added for another 15 min. Th e 1-ml HBSS solutions were taken out from the wells. glutathione and EGTA were added to the solutions to the fi nal concentration of 2 mM to prevent autooxidation of dopamine. Th e amounts of DA in HBSS solutions were measured by reverse phase HPLC (ESA Model 582 with ESA MD150 × 3.2 column, at 0.6 ml min − 1 fl ow rate in MD-TM mobile phase) coupled with electrochemical detection 17 (ESA Coulochem III, E1: − 250 mV, 2 μ A; E2: 350 mV, 2 μ A). Cells in the three wells were lysed in 0.5 N NaOH to measure protein levels, which were used to normalize dopamine release. Spontaneous dopamine release is refl ected in (a), while Ca 2 + -and activity-dependent release is refl ected in (b) -(c).
Specifi c dopamine uptake . Th e iPSC-derived neuronal cultures in 6-well plates were rinsed with 1 ml prewarmed uptake buff er (10 mM HEPES, 130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 10 mM glucose, pH 7.4) three times. Cells were incubated for 10 min at 37 ° C with 1 ml uptake buff er containing 5 μ M dopamine without or with 10 μ M nomifensine (a selective inhibitor of DAT). Aft er the cells were washed at least three times in uptake buff er, they were lysed in 0.1 M perchloric acid with 1 mM EDTA and 0.1 mM sodium bisulphite. Cleared cell lysates were analysed for dopamine on HPLC coupled with electrochemical detection 17 (E1: − 150 mV, 2 μ A; E2: 220 mV, 2 μ A). Th e pellets of cellular proteins were dissolved in 1 ml 0.5 N NaOH to measure protein contents, which were used to normalize dopamine uptake. Specifi c dopamine uptake is refl ected in the diff erence of DA content in the absence and presence of the DAT inhibitor nomifensine. Th e amount of dopamine in the iPSC-derived neuronal cultures without any treatment was also measured.
[ 3 H]CFT binding assay . DAT radioligand binding assay using [ 3 H]CFT was performed with a protocol similar to what was described before 18 . Aft er iPSCderived neuronal cultures in 6-well plates were washed three times at room temperature in binding buff er (10 mM phosphate buff er, pH 7.4, 0.32 M sucrose), they were incubated in 1 ml of binding buff er containing 4 nM [ 3 H]CFT without or with the selective DAT inhibitor GBR12909 (10 μ M) for 2 h at 4 ° C. Th e assay was terminated by three washes with 1 ml of ice-cold binding buff er. Th e neuronal cultures were lysed in 0.5 ml of 1 % SDS for 15 min at room temperature and the entire lysate was measured in a scintillation counter. Non-specifi c binding was defi ned as binding in the presence of 10 μ M GBR12909. It was subtracted from the total binding to derive specifi c [ 3 H]CFT binding. Th e total amounts of cellular proteins were measured in parallel experiments and used to normalize specifi c [ 3 H]CFT binding.
Measurement of protein carbonyls
. Th e levels of protein carbonyls were measured as described before 38 . Protein carbonyls in total cell lysates containing 80 μ g proteins were measured with the Oxyblot protein oxidation detection kit ( Chemicon , Temecula, CA). Intensities of 2,4-dinitrophenyl (DNP)-modifi ed proteins were quantifi ed by densitometry. Background-subtracted signals were normalized against untreated C001 neural cultures. 
